BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12189366)

  • 1. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker.
    Kim MJ; Bertino JS; Gaedigk A; Zhang Y; Sellers EM; Nafziger AN
    Clin Pharmacol Ther; 2002 Aug; 72(2):192-9. PubMed ID: 12189366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects.
    Laine K; Tybring G; Bertilsson L
    Clin Pharmacol Ther; 2000 Aug; 68(2):151-9. PubMed ID: 10976546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
    Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
    Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
    Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.
    Wang LS; Zhou G; Zhu B; Wu J; Wang JG; Abd El-Aty AM; Li T; Liu J; Yang TL; Wang D; Zhong XY; Zhou HH
    Clin Pharmacol Ther; 2004 Mar; 75(3):191-7. PubMed ID: 15001970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping.
    Kim MJ; Nafziger AN; Zhang Y; Sellers EM; Gaedigk A; Bertino JS
    J Clin Pharmacol; 2004 Sep; 44(9):966-73. PubMed ID: 15317824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.
    Roh HK; Dahl ML; Tybring G; Yamada H; Cha YN; Bertilsson L
    Pharmacogenetics; 1996 Dec; 6(6):547-51. PubMed ID: 9014204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy.
    Kimura M; Ieiri I; Wada Y; Mamiya K; Urae A; Iimori E; Sakai T; Otsubo K; Higuchi S
    Br J Clin Pharmacol; 1999 Jan; 47(1):115-9. PubMed ID: 10073749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
    Rost KL; Roots I
    Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
    Sagar M; Seensalu R; Tybring G; Dahl ML; Bertilsson L
    Scand J Gastroenterol; 1998 Oct; 33(10):1034-8. PubMed ID: 9829356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype.
    Herrlin K; Massele AY; Rimoy G; Alm C; Rais M; Ericsson O; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 2000 Aug; 68(2):189-98. PubMed ID: 10976550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
    Bertilsson L
    Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype.
    Marinac JS; Balian JD; Foxworth JW; Willsie SK; Daus JC; Owen R; Flockhart DA
    Clin Pharmacol Ther; 1996 Aug; 60(2):138-44. PubMed ID: 8823231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin.
    Zhou Q; Yamamoto I; Fukuda T; Ohno M; Sumida A; Azuma J
    Eur J Clin Pharmacol; 1999 Mar; 55(1):43-7. PubMed ID: 10206083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
    Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
    Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects.
    Lamba JK; Dhiman RK; Kohli KK
    Clin Pharmacol Ther; 1998 Apr; 63(4):422-7. PubMed ID: 9585796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
    Aoyama N; Tanigawara Y; Kita T; Sakai T; Shirakawa K; Shirasaka D; Kodama F; Okumura K; Kasuga M
    J Gastroenterol; 1999; 34 Suppl 11():80-3. PubMed ID: 10616772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.
    Isaza C; Henao J; Martínez JH; Sepúlveda Arias JC; Beltrán L
    BMC Clin Pharmacol; 2007 Jul; 7():6. PubMed ID: 17623107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
    Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
    Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.